1-氨基甲酰哌啶-4-羧酸 | 851168-77-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-氨基甲酰哌啶-4-羧酸
• 英文名称: 1-carbamoylpiperidine-4-carboxylic Acid
• CAS: 851168-77-9；467430-50-8
• 化学式: C₇H₁₂N₂O₃
• mdl: MFCD06655891
• 分子量: 172.18
• InChiKey: SIYQEPJUSPTPGW-UHFFFAOYSA-N

物化性质

• 熔点：
  196°C
• 沸点：
  372.8±52.0 °C(Predicted)
• 密度：
  1.343±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  (3aS,4R,7aS)-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-methyl-4-(2-methylphenyl)octahydro-5H-pyrrolo[3,4-c]pyridine-5-carboxamide 、 1-氨基甲酰哌啶-4-羧酸 生成 (3aS,4R,7aS)-2-{[1-(aminocarbonyl)piperidin-4-yl]carbonyl}-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-methyl-4-(2-methylphenyl)octahydro-5H-pyrrolo[3,4-c]pyridine-5-carboxamide
  参考文献：
  名称：

  6.5 -PYRROLOPIPERIDINE TACHYKININ RECEPTOR ANTAGONISTS

  摘要：

  本发明涉及某些羟甲基醚羟异吲哚啉化合物，其作为神经激肽-1（NK-1）受体拮抗剂和速激肽，特别是物质P的抑制剂具有用途。本发明还涉及含有这些化合物作为活性成分的制药配方以及在治疗某些疾病，包括恶心、尿失禁、下尿路症状、抑郁症和焦虑症中使用这些化合物和它们的配方。

  公开号：

  US20100197724A1

文献信息

• LTA4H modulators and uses thereof
  申请人：Barchuk William T.

  公开号：US20080194630A1

  公开（公告）日：2008-08-14

  Leukotriene A4 hydrolase (LTA4H) inhibitors, compositions containing them, and methods of use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation.

  白三烯A4水解酶（LTA4H）抑制剂，含有它们的组合物，以及用于抑制LTA4H酶活性和治疗、预防或抑制炎症和/或与炎症相关疾病的方法。
• [EN] BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS<br/>[FR] DERIVES DE BENZIMIDAZOLE, DE BENZTHIAZOLE ET DE BENZOXAZOLE ET UTILISATION DE CEUX-CI COMME MODULATEURS LTA4H
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005012296A1

  公开（公告）日：2005-02-10

  Leukotriene A4 hydrolase (LTA4H) inhibitors of formula I, compositions containing them, and their use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation, wherein X is selected from the group consisting of NR5, O, and S, with R5 being one of the H and CH3; Y is selected from the group consisting of CH2 and O; R4 is selected from the group consisting of H, OCH3, Cl, F, Br, I, OH, NH2, CN, CF3.

  白三烯A4水解酶（LTA4H）的抑制剂I式，含有它们的组合物，以及它们用于抑制LTA4H酶活性和治疗、预防或抑制炎症和/或与炎症相关疾病的用途，其中X从NR5、O和S组成的组中选择，其中R5是H和CH3中的一个；Y从CH2和O组成的组中选择；R4从H、OCH3、Cl、F、Br、I、OH、NH2、CN、CF3组成的组中选择。
• DIAMINE DERIVATIVE
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1847530A1

  公开（公告）日：2007-10-24

  The present invention provides a diamine derivative or the like represented by the general formula (I): wherein Q represents an oxygen atom or the like, RG represents a hydrogen atom or the like, RI represents (wherein p and r may be the same or different, and each represents 0 or the like, RA represents a hydrogen atom or the like, and RB and Rc may be the same or different, and each represents a hydrogen atom or the like), RH represents a hydrogen atom or the like, and RJ represents: (wherein q and s may be the same or different, and each represents 0 or the like, RD represents a hydrogen atom or the like, and RE and RF may be the same or different, and each represents a hydrogen atom or the like) or the like}, etc.

  本发明提供了一种二胺衍生物等，由通式(I)表示：其中Q表示氧原子等，RG表示氢原子等，RI表示（其中p和r可以相同或不同，各自表示0或等，RA表示氢原子等，RB和RC可以相同或不同，各自表示氢原子等），RH表示氢原子等，RJ表示：（其中q和s可以相同或不同，各自表示0或等，RD表示氢原子等，RE和RF可以相同或不同，各自表示氢原子等）等}，等等。
• [EN] AMINOMETHYL QUINOLONE COMPOUNDS<br/>[FR] COMPOSÉS D'AMINOMÉTHYL-QUINOLONE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013007676A1

  公开（公告）日：2013-01-17

  The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula (I): wherein the variables are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.

  这项发明涉及JNK抑制剂及相应的用于抑制JNK和治疗JNK介导的疾病的方法、配方和组合物。该申请披露了JNK抑制剂，如下所述的化学式(I)：其中变量如本文所定义。本文披露的化合物和组合物可用于调节JNK的活性并治疗与JNK活性相关的疾病。还披露了用于抑制JNK和治疗JNK介导的疾病等的方法和配方，以及用于制备上述化合物和相应组合物的过程。
• Pyrazole compounds and their use as antidiabetes agents
  申请人：Takagi Masaki

  公开号：US20070032529A1

  公开（公告）日：2007-02-08

  The present invention provides a pyrazole compound that has liver glycogen phosphorylase inhibitory activity and is useful as a therapeutic or prophylactic agent for diabetes, the pyrazole compound represented by the following general formula (I): wherein Ring Q represents an aryl or heteroaromatic group, R 1 represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group, R 2 represents a halogen atom, a C 1-6 alkyl group, a C 1-6 alkoxy group or an azido group, R 3 represents a halogen atom, a hydroxyl group, a C 1-6 alkyl group, a halo C 1-6 alkyl group, a C 1-6 alkoxy group, an azido group, an amino group, an acylamino group or a C 1-6 alkylsulfonylamino group, R 4 and R 5 are identical with or different from each other and represent a hydrogen atom, a substituted or unsubstituted C 1-6 alkyl group, a C 3-8 cycloalkyl group, a substituted or unsubstituted saturated heterocyclic group, a substituted or unsubstituted aryl group, a C 7-14 aralkyl group, a heteroaromatic group, or the like, or a pharmacologically acceptable salt thereof.

  本发明提供了一种具有肝糖原磷酸化酶抑制活性的吡唑化合物，用作糖尿病的治疗或预防剂，所述吡唑化合物由以下通用式（I）表示：其中环Q代表芳基或杂芳基，R1代表氢原子、卤原子、C1-6烷基或C1-6烷氧基，R2代表卤原子、C1-6烷基、C1-6烷氧基或偶氮基，R3代表卤原子、羟基、C1-6烷基、卤代C1-6烷基、C1-6烷氧基、偶氮基、氨基、酰胺基或C1-6烷基磺酰胺基，R4和R5彼此相同或不同，代表氢原子、取代或未取代的C1-6烷基、取代或未取代的C3-8环烷基、取代或未取代的饱和杂环基、取代或未取代的芳基、C7-14芳基烷基、杂芳基等，或其药理学上可接受的盐。